# PRFX catalysts: PRF Technologies Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/prfx/catalysts

> PRF Technologies Ltd. (PRFX) has no upcoming catalysts in this calendar. The latest recorded is the OcuRing (ocuring) trial start, late 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | PRF Technologies Ltd. |
| Ticker | PRFX (Nasdaq) |
| SEC CIK | 1801834 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/prfx |

## Cash runway

Cash $10.8M as of 2025-12-31; quarterly burn $989K; about 32.7 months of runway at that rate (XBRL company facts, accession 0001178913-26-001782).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2023 | [PRF-110 trial start](https://sec-api.dev/pdufa/prf-110) | PRFX |  | completed | "In March 2023, we initiated our first Phase 3 clinical trial of PRF-110 in the United States, for pain treatment of patients undergoing bunionectomy, successfully completing the first part of the Phase 3 clinical study soon thereafter in a PK study of 15 patients undergoing bunionectomy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1801834/000117891325003458/exhibit_99-2.htm)) |
| Nov 2024 | [PRF-110 topline data readout](https://sec-api.dev/pdufa/prf-110) | PRFX |  | completed, met | "In November 2024, we announced that the initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1801834/000117891325003458/exhibit_99-2.htm)) |
| 2H 2026 | [PRF-110 trial start](https://sec-api.dev/pdufa/prf-110) | PRFX |  | scheduled | "Following IND clearance and completion of trial-startup activities, PRF plans to initiate a multi-center Phase II clinical trial in the United States, with patient enrollment expected to begin in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1801834/000117891326002264/exhibit_99-1.htm)) |
| late 2026 | [OcuRing (ocuring) trial start](https://sec-api.dev/pdufa/ocuring) | PRFX |  | scheduled | "Nano Limited; the expected commencement of patient enrollment in the Phase 2 clinical trial of OcuRing™-K before year-end 2026;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1801834/000117891326005196/exhibit_99-1.htm)) |

## Drugs

- [OcuRing (ocuring)](https://sec-api.dev/pdufa/ocuring): 
- [PRF-110](https://sec-api.dev/pdufa/prf-110): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/prfx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PRFX catalysts: PRF Technologies Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/prfx/catalysts

```bibtex
@misc{secapidev_companies_prfx_catalysts_20261116,
  title        = {PRFX catalysts: PRF Technologies Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/prfx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_prfx_catalysts_20261116","title":"PRFX catalysts: PRF Technologies Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/prfx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
